ストックスクリーナーアプリを入手
71.70
0.23%
0.1707
Halozyme Therapeutics Inc (HALO) 最新ニュース
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance
Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com
Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Insider Sell Alert: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan - Stock Titan
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 26% Potential Upside for Investors - DirectorsTalk Interviews
Halozyme earnings up next: Can drug delivery platform sustain growth? By Investing.com - Investing.com Nigeria
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Implied volatility surging for Halozyme Therapeutics stock options - MSN
Halozyme Therapeutics Q1 earnings call highlights - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - Yahoo Finance
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme posts strong Q1 earnings, boosts share buyback with $1B program amid robust royalty growth - Pluang
Halozyme Therapeutics: Royalty King (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Alteogen Gains Momentum in Patent Defense for Merck's Subcutaneous Keytruda - thelec.net
Halozyme Therapeutics (HALO) Stock Analysis: A 27.3% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
0.16%
1.10%
大文字化:
|
ボリューム (24 時間):